A phase II trial of carboplatin and TS-1 for advanced or recurrent squamous cell lung cancer with the index of Ccr score
- Conditions
- Squamous cell lung cancer
- Registration Number
- JPRN-UMIN000005875
- Lead Sponsor
- OULCSG
- Brief Summary
In the 33 patients analyzed, the primary endpoint response rate was 30.3% (95% confidence interval: 15.6-48.7%), which met the threshold 15%. The disease control rate was 75.8%. The median PFS and OS were 3.5 and 11.3 months, respectively. Ten patients received maintenance S-1, and the median PFS was 5.3 months. Grade 3/4 toxicities with a frequency of more than 5% were all controllable.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Not provided
1)With adjuvant chemotherapy 2)The patients who have interstitial change 3)Allergy of the medication 4)Double cancer 5)Un-controlled pleural effusion and ascites 6)Severe complications, including AMI, un-controlled angina pectoris, and un-controlled diabetes and hypertension 7)Symptomatic brain metastasis 8)Radiation therapy which has thoracic field 9)The patients who treat with flucytosine 10)Pregnancy,breast feeding or wish of future bearing 11)Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method